New TB vaccines enter human testing – could they prevent a global killer?
NCT ID NCT05537038
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested two experimental vaccines (BNT164a1 and BNT164b1) against tuberculosis in 120 healthy adults who had never been exposed to TB or received the BCG vaccine. The main goal was to check safety and find the best dose. Participants received three doses of either a vaccine or a placebo, and researchers monitored side effects and immune responses for several months.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBERCULOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CRS Clinical Research Services Berlin GmbH
Berlin, 13627, Germany
-
CRS Clinical Research Services Mannheim GmbH
Mannheim, 68167, Germany
-
emovis GmbH
Berlin, 10629, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune profiling unlock the hidden stages of tuberculosis?
- Could inhaled TB drugs curb the spread of Drug-Resistant tuberculosis?
- Can new tests predict who will develop active TB?
- Could a 3-Month TB cocktail replace the standard 6-Month regimen?
- Could a simple blood test ensure the right TB dose for kids?
- Community-Driven TB screening aims to reach vulnerable immigrants